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Abstract
The National Institute for Health and Care Excellence (NICE), as part of the institute’s single technology appraisal (STA) 
process, invited the company that makes obinutuzumab (Roche Products Limited) to submit evidence of the clinical and 
cost effectiveness of the drug in combination with chemotherapy, with or without obinutuzumab as maintenance therapy 
for adult patients with untreated, advanced follicular lymphoma (FL) in the UK. Kleijnen Systematic Reviews Ltd (KSR), 
in collaboration with Erasmus University Rotterdam, was commissioned to act as the Evidence Review Group (ERG). This 
paper describes the company’s submission, the ERG review, and NICE’s subsequent decisions. The clinical evidence was 
derived from two phase III, company-sponsored, randomised, open-label studies. Most evidence on obinutuzumab was based 
on the GALLIUM trial that compared obinutuzumab in combination with chemotherapy as induction followed by obinu-
tuzumab maintenance monotherapy with rituximab in combination with chemotherapy as induction followed by rituximab 
maintenance monotherapy in previously untreated patients with FL (grades 1–3a). Long-term clinical evidence was based 
on the PRIMA trial, studying the benefit of two years of rituximab maintenance after first-line treatment in patients with FL. 
The cost-effectiveness evidence submitted by the company relied on a partitioned survival cost-utility model, implemented 
in Microsoft® Excel. The base-case incremental cost-effectiveness ratio (ICER) presented in the company submission was 
<£20,000 per quality-adjusted life-year (QALY) gained. Although the ERG concluded that the economic model met the 
NICE reference case to a reasonable extent, some errors were identified and several assumptions made by the company were 
challenged. A new base-case scenario produced by the ERG suggested an ICER that was higher than the company base case, 
but still below £30,000 per QALY gained. However, some ERG scenario analyses were close to or even above the threshold. 
This was the case in particular for assuming a treatment effect that did not extend beyond trial follow-up. These results led 
to an initial negative recommendation by the appraisal committee. Subsequently, the company submitted a revised base 
case focusing on patients at intermediate or high risk of premature mortality. Simultaneously, a further price discount for 
obinutuzumab was granted. In addition to the company’s revised base case, the ERG suggested a restriction of the treatment 
effect to 5 years and implemented biosimilar uptake and cheaper prices for rituximab. All of these adjustments did not exceed 
£30,000 per QALY gained and therefore the use of obinutuzumab for patients with advanced FL and a Follicular Lymphoma 
International Predictive Index (FLIPI) score of two or more could be recommended.
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Key Points for Decision Making 
Evidence from immature randomised clinical trials can 
be used to inform cost-effectiveness analysis. However, 
the degree of uncertainty arising from using this imma-
ture data may lead to a negative recommendation by the 
appraisal committee even if the incremental cost-effec-
tiveness ratio is below £30,000 per quality-adjusted life-
year gained. Narrowing down the patient population and 
granting a further discount on the price of the interven-
tion may decrease the decision uncertainty and lead to a 
positive recommendation by the appraisal committee.
The use of biosimilars is encouraged by NHS England 
and should therefore be considered in the cost-effective-
ness model.
Obinutuzumab can be considered cost effective for the 
first-line treatment of adult patients with advanced fol-
licular lymphoma and a Follicular Lymphoma Interna-
tional Predictive Index (FLIPI) score of two or more, 
given the (confidential) discount agreed in the patient 
access scheme.
1 Introduction
Within the United Kingdom (UK) National Health Service 
(NHS), the National Institute for Health and Care Excel-
lence (NICE) may recommend the use of new and exist-
ing medicines and treatments through single technology 
appraisals (STAs) [1]. During such appraisals, the NICE 
Appraisal Committee (AC) reviews clinical and economic 
evidence on the technology under investigation based on 
the company submission (CS), taking into account the 
critique of a report from an appointed independent Evi-
dence Review Group (ERG) as well as advice from other 
consultees (e.g. patients, experts and other stakeholders). 
After consideration of all the relevant evidence, the AC for-
mulates preliminary guidance in the form of the Appraisal 
Consultation Document (ACD) as to whether or not to 
recommend the technology. The stakeholders are invited 
to comment on this ACD and the submitted evidence. A 
subsequent ACD may be produced or a Final Appraisal 
Determination (FAD) is issued. Once recommended by 
NICE, the NHS is legally obliged to fund and resource the 
appraised technology so that the patients’ right to access 
these technologies is ensured [1]. This paper presents a 
summary of the ERG report and the development of the 
NICE guidance based on the AC’s findings for the STA of 
obinutuzumab in combination with chemotherapy as an 
induction therapy, followed by obinutuzumab maintenance 
monotherapy, for the first-line treatment of patients with 
advanced follicular lymphoma. Full details of all the rel-
evant appraisal documents can be found on the NICE web-
site (TA513) [2].
2  The Decision Problem
Arising from lymphocytes, lymphomas are a heterogene-
ous group of malignancies of which about 90% are diag-
nosed as non-Hodgkin lymphomas (NHL) [3]. In the UK, 
NHL are the sixth most common type of cancer [4]. With 
an annual incidence rate of 3.2 per 100,000, follicular lym-
phomas (FL) constitute the third most common subtype of 
NHL in UK [4]. The median age at diagnosis for FL in the 
UK is about 65 years, with a 5-year relative survival rate 
of 86.5% [5, 6]. Survival of patients with FL can be pre-
dicted with either the Follicular Lymphoma International 
Predictive Index (FLIPI) [7], or its revised version, known 
as FLIPI2 [8]. The FLIPI comprises a set of five predictive 
parameters (age, Ann Arbor stage, haemoglobin, serum lac-
tate dehydrogenase [LDH] level, and number of nodal sites), 
discriminating patients into three risk groups (low, interme-
diate and high) [7]. FLIPI2 builds on five parameters as well, 
but only haemoglobin and age are shared with the FLIPI 
(β2-microglobulin, longest diameter of the largest involved 
node, and bone marrow involvement are the other three) [8]. 
The lower the FLIPI/FLIPI2 score, the better the prognosis 
as well as overall survival (for FLIPI) and progression-free 
survival (for FLIPI2) of patients with FL. A FLIPI score of 
0–1 is regarded as low risk while a score of 2 or above sig-
nifies intermediate to high risk. Due to the indolent nature 
of the disease, most patients present with advanced stages 
at first diagnosis and therefore require systemic treatment 
[5, 9].
In the UK, patients with advanced, symptomatic FL 
receive rituximab-containing treatment regimens as first-
line therapy options, followed by 2 years of maintenance 
therapy. However, despite receiving immunochemotherapy, 
an estimated 20% of patients with FL experience disease 
progression within 2 years of diagnosis [10]. Treatment for 
patients with advanced stage aims to control the disease, 
which is typified by a chronic course comprised of repeated 
relapses, treatment and progression.
As a type II anti-CD20 antibody, obinutuzumab received 
marketing authorisation from the European Medicine 
Agency (EMA) for previously untreated chronic lympho-
cytic leukaemia (CLL) in July 2014 [11]. In April 2016 
and July 2017, the EMA extended the indication for obi-
nutuzumab to FL [12, 13]. The scope for this STA set by 
NICE was to assess the use of obinutuzumab in combina-
tion with chemotherapy, with or without obinutuzumab as 
maintenance therapy (obin−chemo+obin) for people with 
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untreated advanced FL in the UK. Mentioned comparators 
were rituximab monotherapy (although there was no mar-
keting authorisation in the UK for this indication at time of 
appraisal), rituximab-based chemotherapy with or without 
rituximab maintenance treatment, and bendamustine mono-
therapy (no marketing authorisation in the UK at the time 
of appraisal).
3  The Independent Evidence Review Group 
(ERG) Review
Kleijnen Systematic Reviews Ltd (KSR), in collaboration 
with the Erasmus University Rotterdam, constituted the ERG 
and reviewed the evidence on the clinical and cost effective-
ness of obin−chemo+obin treatment for the first-line treat-
ment of patients with advanced FL.
The ERG critically reviewed the evidence in the CS, the 
company’s responses to clarification questions (RCQ) from 
the ERG, and the evidence provided after the publication 
of the ACD. Furthermore, the ERG explored the impact 
of assumptions on the incremental cost-effectiveness ratio 
(ICER), revised the economic model and explored additional 
scenario analyses.
3.1  Summary of the Clinical Evidence
The company conducted a systematic review to identify 
published and unpublished randomised clinical trial (RCT) 
evidence on the use obinutuzumab in previously untreated 
FL. Searches were carried out in June 2015 via PubMed, 
Embase and the Cochrane Central Register of Controlled 
Trials (CENTRAL). Updated searches were reported for 
March and June 2017. At each time, separate supplementary 
searches of congress proceedings, clinical trial registries, 
cancer association networks, and Health Technology Assess-
ment (HTA) agency websites were conducted to detect rel-
evant unpublished and grey information. Ultimately, only 
one study was considered relevant to the decision problem. 
Therefore, the evidence on the efficacy of obinutuzumab was 
entirely based on GALLIUM, a phase III, open-label, multi-
centre RCT (BO21223, NCT01332968) [14].
GALLIUM was conducted at 177 trial centres in 18 
countries with 21% of the participants (n = 293) being from 
the UK. For this study, 1401 adult patients (≥ 18 years) 
with previously untreated, advanced indolent NHL were 
randomly assigned to two treatment arms. All analyses 
were based on the 1202 patients in the FL subpopulation, 
which included those with FLIPI scores from 0 upwards. 
One group received rituximab in combination with chemo-
therapy (R-chemo) as induction followed by rituximab (R) 
as maintenance. The other group received obinutuzumab in 
combination with chemotherapy (obin-chemo) as induction, 
followed by obinutuzumab (obin) as maintenance.
The primary outcome was investigator-assessed progres-
sion-free survival (INV-PFS). Secondary outcome measures 
included independent review committee-rated progression-
free survival (IRC-PFS) and overall survival (IRC-OS); 
response rates at induction, maintenance and follow-up; 
adverse events (AEs); as well as health-related quality of 
life (HRQoL). The latter was assessed using the disease-spe-
cific Functional Assessment of Cancer Therapy for Patients 
with Lymphoma (FACT-Lym) instrument and the European 
Quality of Life (EuroQol) ED-5D-3L questionnaire.
Data reported in the CS were taken from the primary 
analysis of GALLIUM with a clinical cut-off in January 
2016. Since the updated cut-off data were marked as aca-
demic in confidence, all data presented in this publication 
focus on the FL subpopulation at the January 2016 cut-off 
of the GALLIUM trial only.
The median age of the FL population in GALLIUM was 
59 years (range 23–88 years) with a female ratio of 53.2%. 
Of the three different chemotherapy regimens permitted, the 
most frequently used was bendamustine (57%), followed by 
CHOP (33%) and CVP (10%). Induction therapy was com-
pleted for 598 and 594 patients in the R-chemo and obin-
chemo arm, respectively. Subsequently, 527 patients in the 
R-chemo and 539 patients in the obin-chemo arm received 
maintenance therapy. These patients had achieved either a 
complete response (CR) or a partial response (PR) at this 
stage. Stable disease (SD) was achieved by 17 patients 
who therefore underwent observation. Patients in both 
maintenance and observation were followed clinically on 
a 2-monthly basis for 2 years. A total of 341 patients in the 
R-chemo arm and 361 patients in the obin-chemo arm com-
pleted maintenance therapy. The reported overall median 
observation time was 34.4 months (range 0.1–54.5 months) 
in the R-chemo arm and 34.8 months (range 0.0–53.8 
months) in the obin-chemo arm. The proportion of patients 
who had been observed for at least 2 and 3 years at the clini-
cal cut-off was 87.7% and 44.1% in the R-chemo arm and 
91.3% and 45.1% in the obin-chemo arm, respectively.
At the January 2016 cut-off, median INV-PFS as well 
as OS were not reached in both treatment arms. While the 
IRC-PFS was also not reached for the obin-chemo arm, 
it was reported with 51.2 (95% CI 47.1–not estimated) 
months for the R-chemo arm. Hazard ratios (HRs) compar-
ing obin-chemo+obin with R-chemo+R were consistent 
and favoured obin-chemo+obin in both INV-PFS (HR 0.66 
[95% CI 0.51–0.85; p = 0.0012]) and IRC-PFS (0.71 [95% 
CI 0.54–0.93; p = 0.0138]). In the subgroup analyses, only 
low-risk FLIPI scores showed an HR >1.00 (HR 1.17 [95% 
CI 0.63–2.19]), while HRs of all other FLIPI scores ranged 
from 0.40 to 0.86.
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Treatment-related AEs were observed in 94.8% of patients 
in the obin−chemo+obin arm and in 91.6% of patients in the 
R-chemo+R arm. Two System Organ Classes were more 
commonly observed (≥10%) in the obin-chemo+obin arm 
when compared with R-chemo+R: general disorders and 
administration site conditions (50.8% vs 60.8%) as well as 
injury, poisoning and procedural complications (49.1% vs 
59.2%). In addition, a higher incidence of severe adverse 
event (SAEs) could be observed in the obin-chemo+obin 
arm than in the R-chemo+R arm (46.1% vs 39.9%).
For both FACT-Lym questionnaire subscales and EQ-
5D-3L scales, no notable differences between the treatment 
arms were detected at any time.
It is worthwhile mentioning that data for the late pro-
gressive disease states were taken from the PRIMA study, a 
phase III RCT of rituximab maintenance therapy in patients 
with high tumour burden FL that responded to rituximab 
plus chemotherapy induction. Characteristics of the PRIMA 
trial are reported elsewhere [15, 16].
3.1.1  Critique and Conclusion of the Clinical Evidence 
and Interpretation
Regarding the systematic review, the ERG concluded that 
the population of the review was in line with the scope but 
the comparators were not. This was because the company 
had only included studies with a rituximab arm. As a devia-
tion from the scope set by NICE, the company chose to con-
sider only one comparator: rituximab in combination with 
chemotherapy, followed by rituximab maintenance treatment 
in patients achieving a response, which was criticised by the 
ERG. In addition, the ERG criticised that both data extrac-
tion and quality assessment of the studies retrieved by the 
literature search were not conducted by two reviewers inde-
pendently. However, the ERG acknowledged that the GAL-
LIUM trial was appropriate for the decision problem at hand 
due to its relevant population and reasonable proportion of 
UK patients (21%). The attention of the AC was drawn to the 
exclusion of grade 3B lymphoma in GALLIUM, which was 
found to be in line with the anticipated treatment with obi-
nutuzumab. Although three different types of chemotherapy 
were offered in the trial, GALLIUM was not designed to 
investigate differences between these regimens. Therefore, 
the ERG could not decide whether the breakdown of regi-
mens in the trial would reflect UK clinical practice. Due to 
GALLIUM being an open-label trial, the ERG concluded 
that the results of the IRC would be less prone to bias than 
the investigator results. Furthermore, although the follow-up 
duration of the trial was reasonable, data were judged not 
fully mature for the main outcomes.
In its clarification response, the company acknowledged 
that the GALLIUM cohort might on average be younger 
than the average UK patient population with FL, which was 
confirmed by clinical experts consulted by the company and 
data from the Haematological Malignancy Research Net-
work (HMRN) [17]. The ERG therefore adjusted the age at 
baseline in its own base-case model.
3.2  Summary of the Cost‑Effectiveness Evidence
The company conducted several literature searches to detect 
studies on cost effectiveness, health effects, as well as on 
cost and healthcare resource use. For the cost-effectiveness 
search, none of the retrieved references were considered 
relevant. Therefore, the company conducted a de novo eco-
nomic evaluation of obinutuzumab in combination with 
chemotherapy compared with rituximab in combination 
with chemotherapy for the first-line treatment of patients 
with advanced FL.
For this purpose, the company developed an Excel-based 
five-state cohort transition Markov model with the following 
health states: two PFS states for on and off treatment, two 
progressed disease (PD) states for early and late PD, and 
death. All simulated observations start in the PFS health 
state on treatment (obin-chemo+obin or R-chemo+R). Only 
patients responding to induction received maintenance (as 
per licence indication), which was only offered until progres-
sion or for a maximum of 2 years. Patients are considered 
‘off-treatment’, when they complete or discontinue treatment 
in the PFS state. From the latter state, patients can remain in 
either PFS (on- or off-treatment) or transition due to progres-
sive disease or death. It is assumed that the time to progres-
sion after initial treatment is predictive for post-progression 
mortality and OS. In particular, patients progressing within 
the first 2 years of initial treatment have significantly worse 
survival outcomes than those who did not progress that early 
[10, 18]. To account for different outcomes and costs to the 
cohorts of patients who experience early or late progression, 
two PD states were introduced. Once patients enter any of 
the two PD states, they can only remain in this state until 
death. The cumulative deaths from PFS and early as well 
as late PD states were used to calculate OS in the model. 
Survival estimates beyond the observed trial duration were 
extrapolated using several parametric functions. The popu-
lation considered in the de novo analysis was equal to the 
GALLIUM cohort in terms of average age, body weight, 
height and body surface area (BSA) (see Table 1).
The company argued that, based on the observed long-
term follow-up in the PRIMA study and the expert opin-
ion from clinical advisors, there was no evidence of a finite 
duration of treatment effect in treatments of FL (including 
obin-chemo+obin and R-chemo+R). However, for the base-
case analysis, a treatment effect duration of 9.75 years was 
assumed, based on the PRIMA study. This assumption was 
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tested in the sensitivity analysis for its robustness with a 
minimum and maximum assumed treatment effect duration 
of 5 years and an infinite time duration, respectively.
The transition probabilities between the different model 
states were estimated from parametric survival functions fit-
ted to the relevant data for the time to treatment discontinu-
ation (TTTD), PFS, and post-progression survival (PPS). 
Considered distributions were exponential, Weibull, log-
logistic, log-normal, gamma and Gompertz. Their good-
ness of fit to the GALLIUM data was assessed with both 
the Akaike and Bayesian Information criterion (AIC/BIC).
In the model, OS was calculated as the sum of the time 
spent in both PFS and the two PD health states (early and 
late). For the PFS and early PD mortality estimates, the com-
pany relied on the investigator assessed data of the GAL-
LIUM trial. Since in GALLIUM no PPS events in late pro-
gression were observed, late PD mortality estimates were 
based on the PRIMA study.
For the CS base-case model, long-term PFS and early 
PD were modelled with an exponential distribution. The 
monthly probability of transitioning from PFS to death was 
based on the UK age-specific all-cause mortality rate or the 
PFS death rates in GALLIUM (whichever occurred first). 
The same method was applied for the PPS probabilities; 
except that late PD mortality rates were estimated using 
data from the PRIMA trial (instead of GALLIUM). This 
was necessary because the GALLIUM data was premature.
HRQoL utilities for the PFS states were based on EQ-5D 
values collected in the GALLIUM trial. However, since 
long-term EQ-5D values from this trial were considered 
immature, the utility inputs for the progressed model states 
were based on utilities elicited in another study that had 
originally been commissioned by Roche [19]. Health-
state–related costs used in the model consisted of costs for 
medication (induction and maintenance), supportive care, 
subsequent treatment in PD, transportation and adverse 
events. Relevant medication costs included those of obinu-
tuzumab, bendamustine, CHOP, CVP and rituximab. The 
latter were based on 2017 UK reference prices [20, 21]. No 
vial sharing was assumed.
For both costs and utilities, a 3.5% discount rate was 
applied. In addition, the company conducted a one-way 
deterministic sensitivity analysis, several scenario analy-
ses and a probabilistic sensitivity analysis (PSA) to explore 
parametric and structural uncertainty.
In the RCQ, the initial 40-year time horizon of the model 
was set to 50 years, following the ERG’s request.
In the final model submitted by the company, the base-
case ICER (cost per quality-adjusted life-year [QALY] 
gained) was lower than £20,000; the threshold set by NICE 
being somewhere between £20,000 and £30,000, depending 
on plausibility of the evidence [22]. In addition, in the PSA 
results, it was observed that the ICER never reached this 
threshold. Scenario analyses revealed that the assumptions 
on the length of treatment effect (no finite duration vs 5 
years), the discount values (3.5% vs 1.5%) and the choice of 
the parametric survival curve for the PFS states (exponential 
vs Weibull) had the highest impact on the ICER, but did not 
exceed the NICE threshold. In general, all ICERs presented 
by the company (base case, PSA and scenario) were below 
£30,000 per QALY gained.
3.3  Critique of the Cost‑Effectiveness Evidence 
and Interpretation
After assessing the company’s submitted evidence and 
model, the ERG concluded that, although the cost-effective-
ness searches were well documented and reproducible, there 
were concerns regarding inclusion of a ‘line of treatment’ 
facet that was overly restrictive. Revised searches were 
provided during the clarification process, which retrieved 
additional references. Despite the revision of the strategies, 
errors in the Cochrane Library search syntax were still pre-
sent. The additional studies identified were not found to be 
relevant for the decision problem and were not included.
The economic model met the NICE reference case to a 
reasonable extent. Nevertheless, the ERG found that devia-
tions might have occurred in both measurement and valu-
ation of HRQoL. Other deviations included the company’s 
choice of the intervention and the comparator. In general, the 
model was in line with the company’s formulated decision 
problem but only partially in line with the scope. While the 
intervention in the scope was described as “obinutuzumab 
in combination with chemotherapy, with or without obinutu-
zumab maintenance therapy” [23], the company assessed the 
obinutuzumab induction therapy with obinutuzumab mainte-
nance therapy only. Hence, the cost effectiveness of obinutu-
zumab in combination with chemotherapy induction without 
maintenance therapy was not explored in the submission. 
In terms of comparators, the company focussed on rituxi-
mab in combination with chemotherapy but did not include 
other relevant comparators listed in the NICE scope (such 
as rituximab monotherapy or bendamustine monotherapy).
For the model structure, the ERG concluded that the one 
used in the CS was slightly different from other partitioned 
Table 1  Patient baseline characteristics used in the company’s de 
novo economic evaluation
Patient characteristic Baseline value Source
Age (years) 57.9 GALLIUM trial data [14]
Body weight (kg) 75.7
Height (cm) 168.3
Calculated body sur-
face area  (m2)
1.86
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survival models commonly used in oncology [24, 25]. The 
transitions between the health states were explicitly mod-
elled, and in addition to other models, the company had 
also incorporated early and late PD states, which was seen 
by the ERG as a valid addition for modelling FL patients. 
With regards to the analysis and extrapolation of the sur-
vival data, the company had followed the guidance from the 
NICE Decision Support Unit (DSU) [26]. Nevertheless, the 
ERG criticised the choice of the exponential distribution 
for the PFS survival probabilities. Although the company 
had argued that the exponential distribution would result 
in a more conservative estimate when compared with the 
log-logistic distribution, the ERG considered the Weibull 
distribution would represent an even better estimate with 
similar AIC and BIC values. This was because the Weibull 
distribution predicted a 10-year PFS probability of 30.2%, 
which was in line with clinical expert opinion suggesting 
that approximately 60–70% of patients relapse in the first 
10 years after treatment.
Furthermore, due to few mortality events in the GAL-
LIUM study, the company had based the transition prob-
abilities from PFS to death on pooled estimates between 
the treatment arms. Consequently, the probability of dying 
in PFS was assumed equal for both treatment arms. Yet, the 
number of observed deaths between the treatment arms dif-
fered and showed higher mortality in the obinutuzumab arm 
(although not statistically significant). Therefore, the ERG 
recommended applying different transition probabilities per 
arm for both PFS and PPS (early and late PD).
Another point of criticism by the ERG was the assump-
tion of a finite duration of the treatment effect on PFS, 
which was the main driver of the cost-effectiveness results. 
This assumption was made solely on data from the PRIMA 
trial, as long-term data from GALLIUM was lacking. In 
the model base case of the CS, a 9.75-year treatment effect 
was assumed, although the longest follow-up in the GAL-
LIUM trial (at the time of the submission) was 5 years. 
Therefore, the ERG considered a finite treatment effect of 
5 years as a more conservative approach to model the cost 
effectiveness.
Similar to the critique of the clinical evidence, the ERG 
criticised the use of INV-PFS data instead of the IRC-PFS 
data.
3.4  Additional Exploratory Analysis Conducted 
by the ERG
After careful consideration of all input parameter assump-
tions in the company’s base case, the ERG defined a new 
base-case scenario, including multiple adjustments to the 
company’s base-case economic model. The adjustments 
were categorised following the suggestions of Kaltenthaler 
et al. [27]:
• Fixing errors (correcting the model where the company’s 
electronic model was unequivocally wrong).
• Fixing violations (correcting the model where the ERG 
considered that the NICE reference case, scope or best 
practice has not been adhered to).
• Matters of judgement (amending the model where the 
ERG considers that reasonable alternative assumptions 
are preferred).
Ultimately, the ERG corrected five errors, three viola-
tions, had four matters of judgement, and tested four alter-
native scenarios (see Appendices 2 and 3 in the electronic 
supplementary material for a complete list of all items). The 
most influential adjustments to the company’s base-case 
model were (1) choosing the IRC-PFS data together with a 
Weibull distribution for the PFS extrapolation, (2) applying 
age-dependant utility decrements, (3) increasing the popula-
tion’s age at baseline, and (4) considering different mortality 
rates per treatment arm.
The ERG-revised base-case ICER did not exceed the 
£30,000 threshold per QALY gained. Simultaneously, in 
more than 50% of the PSA results, obin-chemo+obin was 
cost effective when compared with R-chemo+R at a £30,000 
per QALY-gained threshold. For all but one scenario analy-
sis, the estimated ICER remained below the £30,000 thresh-
old per QALY. Only assuming a treatment effect duration 
of 5 years (scenario 1a) yielded an ICER above £30,000 
per QALY gained. Choosing different sources for utilities 
in PFS and PD had a substantial impact on the ICER but did 
not exceed the mentioned threshold.
3.5  Conclusion of the ERG Report
The ERG concluded that the GALLIUM trial is a good qual-
ity RCT even though a number of limitations were found. 
For instance, the breakdown of chemotherapy regimens 
(CHOP, CVP and bendamustine) received in the trial may 
not reflect UK clinical practice. Likewise, the median age of 
included individuals in GALLIUM was not reflective of the 
UK FL population. In addition, although the trial had a rea-
sonable follow-up, data were not fully mature for the main 
outcomes. Consequently, the ERG expressed major concerns 
regarding the implementation of the treatment effectiveness. 
More specifically, choosing a shorter duration of the treat-
ment effect than in the CS was a major driver for bring-
ing the ICER close, or even above the £30,000-per-QALY-
gained threshold. Choosing either INV-PFS or IRC-PFS data 
had a substantial impact on the ICER as well, although nei-
ther of the two scenarios exceeded the mentioned threshold. 
Other remaining concerns were related to PFS probability 
distributions, and choosing the same mortality rate for both 
treatment arms. In addition, the ERG could not verify the 
source of the stated utility values for the PD states since 
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they were referenced with an abstract that did not present 
any EQ-5D values [19].
Nevertheless, the ERG-preferred base-case analysis 
resulted in an ICER lower than the £30,000 per QALY 
threshold. Although the ICER seemed to be robust to most 
structural changes explored by the ERG, the scenario analy-
ses conducted by the ERG showed that with different choices 
for the treatment effect duration or the utilities for the PD 
health state, the ICER could exceed the £30,000 per QALY 
threshold.
3.5.1  ERG Research Recommendations
Most notable, the cost-effectiveness analyses could benefit 
from long-term follow-up results from GALLIUM. The 
results could validate some of the key assumptions made 
in the model such as the extrapolation of the PFS paramet-
ric survival functions, the duration of the treatment effect 
and the early/late mortality in the progressed disease state. 
Different mortality assumptions in the progressed disease 
state would lead to different PFS/OS surrogacy implica-
tions, which might have substantial impacts on incremental 
results as elaborated on in other first-line treatment sub-
missions in oncology [28]. In addition, a more recent and 
transparent measure of utility values for the PD health state 
would increase both validity and reliability of the HRQoL 
estimates. Future research should include a comparison of 
obinutuzumab with different chemotherapy regimens such 
as CHOP, CVP and bendamustine to generate more reliable 
estimates for direct treatment comparisons.
3.5.2  Key Methodological Issues
Three methodological issues were expressed by the ERG.
First, the company’s assumption of a finite duration of 
treatment effect on PFS was a major driver for the ICER. 
The treatment effect duration was implemented by setting 
the hazard ratio of the modelled intervention to the com-
parator to one (i.e. no difference in treatment effect), once 
the end of the treatment effect was assumed. Although the 
ERG deemed the technical realisation of the limited treat-
ment effect duration appropriate, some methodical concerns 
on its duration were expressed. The company had based its 
assumption on the PRIMA study, where no finite duration 
of treatment effects between rituximab maintenance treat-
ment compared with ‘observation only’ could be observed 
until the longest follow-up period of 9.75 years. Likewise, 
the assumption of proportional hazards between interven-
tion and comparator arm seemed to hold throughout the 
PRIMA study. This was backed by clinical advisors who 
had suggested that there is no evidence of a finite treatment 
effect in FL treatments, and that this might hold true for 
the comparison of obin-chemo+obin versus R-chemo+R. 
The ERG, by contrast, doubted the generalisability from 
the PRIMA results and their transferability to GALLIUM. 
A visual inspection also suggested that the log-cumulative 
hazard plots for PFS from GALLIUM converged. Hence, the 
proportional hazards assumption most likely did not hold. 
Based on the available evidence, no robust estimate alterna-
tive for a treatment effect duration could be given. On these 
grounds, the ERG proposed a duration of 5 years for the 
treatment effect, as this also reflected the longest follow-up 
time of the GALLIUM study.
Second, due to the immaturity on the GALLIUM data, 
the company used PRIMA data to model the late PD health 
states. This combination of evidence was done without any 
kind of adjustments. However, since patient characteristics 
between the two studies might not be comparable, an unad-
justed use of these data might bias the model estimates.
Third, the company’s assumption of no biosimilar uptake 
for rituximab was deemed implausible.
4  NICE Guidance
4.1  Key Issues Considered by the Appraisal 
Committee
Regarding the clinical evidence, the AC concluded that 
the population of the GALLIUM trial would reflect peo-
ple with advanced FL receiving treatment within the NHS 
to a reasonable extent. However, the trial was judged to be 
underpowered to show a difference in OS. In addition, the 
presented trial data was considered highly immature. Conse-
quently, the AC could not conclude whether obinutuzumab 
could prolong OS when compared with rituximab. Although 
it was acknowledged that obinutuzumab delays disease pro-
gression in the short term, there was still uncertainty about 
a long-term effect on PFS. Furthermore, the AC concluded 
that obinutuzumab is associated with a higher burden of 
adverse events when compared with rituximab. In terms 
of HRQoL, the AC regarded the difference in the EQ-5D 
scores between the GALLIUM trial arms as not statistically 
significant.
For the cost-effectiveness analysis, the AC considered 
several key issues.
First, it recognised substantial uncertainty in the evidence 
base and ICER in terms of the treatment effect duration, 
extrapolation of PFS, resource use and the immaturity of the 
clinical data. In addition, the company’s assumption on the 
treatment effect duration was criticised.
Second, the AC doubted the company’s assumption of a 
0% uptake of biosimilars for rituximab and was aware of two 
biosimilar versions of rituximab that had a market authori-
sation. In addition, the AC was informed that the current 
uptake was increasing and at around 40%.
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Due to the substantial uncertainty in the evidence base 
and ICER, the AC concluded that an acceptable ICER 
threshold would not lie towards the upper part of the range 
of £20,000–£30,000 per QALY gained specified in the NICE 
guide to the methods of technology appraisal [22]. Other 
factors that could substantiate £30,000 per QALY gained, 
such as the innovative nature of obinutuzumab or special 
consideration as a ‘life-extending treatment at the end of 
life’, were ruled out as well.
Ultimately, the ERG updated its base-case analysis incor-
porating the ACs findings. This yielded an expected increase 
in the ICER, rendering the intervention not cost effective at 
the threshold of £30,000 per QALY gained.
4.2  Preliminary Guidance (First Appraisal 
Consultation Document [ACD])
For the first ACD, NICE had considered the initial evidence 
submitted by the company, the testimony of professional 
groups and other stakeholders, as well as the ERG report. In 
September 2017, NICE’s first ACD did not recommend obi-
nutuzumab within its marketing authorisation for untreated 
advanced FL in adults. This recommendation was, however, 
not intended to affect patients that had already started treat-
ment with obinutuzumab before the guidance was published. 
For these patients, no change in funding arrangements would 
take place. A second AC meeting was planned for October 
2017. Until then, all consultees had the chance to react to 
the previously presented evidence.
4.2.1  Response to Preliminary Guidance (First ACD)
In reaction to the first ACD, the company provided an 
updated version of its model including alternative assump-
tions and a revised base-case population. The company 
argued that, although the trial was not powered for indi-
vidual FLIPI subgroups, an analysis focussing only on inter-
mediate and high FLIPI subgroups would result in sufficient 
PFS events for the modelling task. This was in line with the 
EMA requirement to include a statement in the obinutu-
zumab Summary of Product Characteristics that the “[…] 
efficacy in FLIPI low risk (0–1) patients is currently incon-
clusive […]” [29].
With regard to the duration of treatment effect, the com-
pany retained its earlier argument and assumed an infinite 
duration of treatment effect for obinutuzumab. Furthermore, 
the new model assumed independent PFS extrapolations for 
high and intermediate FLIPI subgroups (thus using a non-
proportional hazards assumption) and implemented vial 
sharing.
Biosimilar uptake for rituximab was not considered for 
the base case but was in scenario analyses. The company 
had based this assumption on the recent availability of a 
rituximab biosimilar, claiming that the branded product 
would currently constitute the majority of IV rituximab 
used.
This new analysis yielded an ICER below £20,000 per 
QALY gained, whereas scenarios considering different pro-
portions of market shares and price reductions for rituximab 
biosimilar showed an ICER above £20,000 per QALY.
In reaction to the new company model, the ERG pro-
posed a new (final) base case that assumed a treatment effect 
duration of 5 years, independent PFS extrapolations for high 
and intermediate FLIPI subgroups (thus using a non-pro-
portional hazards assumption), no vial sharing, and a 65% 
update of biosimilar IV rituximab.
In the meanwhile, the company had also agreed on a new 
patient access scheme that would provide a further discount 
to the list price of obinutuzumab. The level of the discount 
is, however, commercial in confidence. The new ERG base 
case (including the new patient access scheme) yielded an 
ICER below £30,000 per QALY gained.
4.3  Final Appraisal Determination (FAD)
Due to the revised economic analyses focussing on higher-
risk subgroups and a further discounted price for obinutu-
zumab and rituximab, the ICER was estimated to be below 
£30,000 per QALY gained. Hence, the AC issued new guid-
ance. In March 2018, the FAD recommended obinutuzumab 
as an option for untreated advanced FL in adults, restricted 
to patients with a FLIPI score of 2 or more (as intended 
by the company’s revised model), provided that the com-
pany would grant the negotiated simple price discount in 
the revised patient access scheme. Just as in the ACD, the 
recommendation was not intended to affect patients that 
had already started treatment with obinutuzumab before 
the guidance was published. For these patients no change in 
funding arrangements would take place.
5  Conclusions
This STA demonstrates that even an ICER of below £20,000 
per QALY gained, as in the first company submission, is no 
guarantee for a positive recommendation by NICE. In fact, a 
high degree of uncertainty in the evidence base of the cost-
effectiveness model might lead to a negative decision by 
NICE, even when the ERG’s base case is below the £30,000 
per QALY gained threshold. Instead, NICE also values the 
degree of uncertainty that, in this case, was expressed by 
some initial ERG scenarios yielding and an ICER close to 
and above the £30,000 threshold.
For this submission, the AC’s major concerns were on the 
degree of uncertainty of the various cost-effectiveness model 
input parameters, particularly the treatment effect duration. 
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Although in this STA most of these parameters were based 
on an RCT, the immaturity of its results did not allow for 
robust estimates concerning the long-term effects of obinu-
tuzumab on PFS. Furthermore, the AC acknowledged both 
cheaper prices and higher uptake of rituximab biosimilars. 
This was based on the 2017–2019 prescribed services com-
missioning for quality and innovation (CQUIN), issued by 
NHS England, encouraging the use of biosimilar products 
to reduce the costs of medicines [30]. Consequently, the AC 
had assumed that most commissioners in England would 
prefer to purchase cheaper biosimilar versions rather than 
branded drugs.
Narrowing down the treatment indication to patients with 
a FLIPI score of 2 or higher, as well as providing a fur-
ther discount on the price for obinutuzumab, could reduce 
the degree of decision uncertainty to the extent that the AC 
could issue a positive recommendation. This final decision 
deviates from the originally intended patient group pro-
posed by the company (no FLIPI score thresholds). Hence, 
when considering the scope of the first CS, NICE adopted 
a ‘restricted’ or ‘optimised’ decision to provide access to 
obinutuzumab while concomitantly reducing the decision 
uncertainty [31, 32].
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